Persistence of large P. aeruginosa aggregates despite reduced airway burden in people with cystic fibrosis on CFTR modulator therapy
Journal of Cystic Fibrosis · 2026-09 · 25 (5) · 771-777
DOI: 10.1016/j.jcf.2026.06.012 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2026-09. Verfasst von Amanda J Morris und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cellular and Molecular Biology, University of Texas Health Science Center at Tyler, Tyler TX, USA. Electronic address: amanda.morris@ut…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Pseudomonas aeruginosa, Pseudomonas Infections, Cystic Fibrosis Transmembrane Conductance Regulator. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Cystic Fibrosis Canada, Cystic Fibrosis Foundation.
Abstract (Originalsprache)
BACKGROUND: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapies improve lung function and reduce airway bacterial burden in people with cystic fibrosis (pwCF); however, chronic Pseudomonas aeruginosa infection can persist and recrudesce. This persistence may be mediated by bacterial aggregation, a phenotype associated with antibiotic tolerance and immune evasion that is not routinely assessed in clinical practice. In this study, we evaluated the impact of CFTR modulation on P. aeruginosa burden and aggregation in sputum from pwCF. METHODS: PwCF with chronic P. aeruginosa infection were enrolled at three Canadian CF centers (2022-2025). Sputum samples were processed using the Microbial Identification after Passive CLARITY Technique (MiPACT), followed by fluorescence in situ hybridization and confocal microscopy. Image analyses quantified P. aeruginosa biovolume and aggregate number, maximum size and size distribution. Mixed-effects models assessed longitudinal and cross-sectional differences by modulator status. RESULTS: Forty-two participants contributed 181 samples; 27 received modulators. Longitudinally, modulator therapy reduced P. aeruginosa biovolume (p = 0.01) and aggregate number (p = 0.04), with no significant changes observed in untreated individuals. Cross-sectional analyses showed no differences in biovolume and aggregate number by treatment status. Maximum aggregate size and the proportion of large aggregates were also comparable between groups with approximately 20% of P. aeruginosa persisting as large aggregates in both groups. CONCLUSIONS: CFTR modulators reduce P. aeruginosa density but not aggregation. Persistent aggregates may represent structurally resilient communities contributing to chronic infection, highlighting aggregation as a potential adjunctive therapeutic target.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cellular and Molecular Biology, University of Texas Health Science Center at Tyler, Tyler TX, USA. Electronic address: amanda.morris@uttyler.edu.
- Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, ON, Canada. Electronic address: shafinaz.eisha@sickkids.ca.
- Division of Microbiology, Department of Pediatric Laboratory Medicine, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada. Electronic address: yvonne.yau@sickkids.ca.
- Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, ON, Canada. Electronic address: sara.goel@sickkids.ca.
- Translational Medicine, Research Institute, Hospital for Sick Children, Toronto, ON, Canada.
- Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: w.depas@pitt.edu.
Förderung
- Cystic Fibrosis Canada
- Cystic Fibrosis Foundation
Zitieren
APA
Morris, A. J., Eisha, S., Yau, Y. C. W., Goel, S., Shaw, M., DePas, W. H., Martin, I., Selvarajah, A., Gaudet, M., Tullis, E., Nguyen, D., & Waters, V. J. (2026). Persistence of large P. aeruginosa aggregates despite reduced airway burden in people with cystic fibrosis on CFTR modulator therapy. Journal of Cystic Fibrosis, 25(5), 771-777. https://doi.org/10.1016/j.jcf.2026.06.012
Vancouver
Morris AJ, Eisha S, Yau YCW, Goel S, Shaw M, DePas WH, et al. Persistence of large P. aeruginosa aggregates despite reduced airway burden in people with cystic fibrosis on CFTR modulator therapy. Journal of Cystic Fibrosis. 2026;25(5):771-777. doi:10.1016/j.jcf.2026.06.012
BibTeX
@article{Morris2026,
author = {Morris, Amanda J and Eisha, Shafinaz and Yau, Yvonne C W and Goel, Sara and Shaw, Michelle and DePas, William H and Martin, Isaac and Selvarajah, Arunan and Gaudet, Mellissa and Tullis, Elizabeth and Nguyen, Dao and Waters, Valerie J},
title = {Persistence of large P. aeruginosa aggregates despite reduced airway burden in people with cystic fibrosis on CFTR modulator therapy},
journal = {Journal of Cystic Fibrosis},
year = {2026},
volume = {25},
number = {5},
pages = {771--777},
doi = {10.1016/j.jcf.2026.06.012}
}
EUVIMED